Comparison of hemodialysis and hemodiafiltration: A long-term longitudinal study  by Kerr, Peter B. et al.
Kidney International, Vol. 41(1992), pp. 1035—1 040
Comparison of hemodialysis and hemodiafiltration: A long-term
longitudinal study
PETER B. KERR, ANGEL ARGILES, JEAN-.LOUIS FLAVIER, BERNARD CANAUD,
and CHARLES M. MI0N
Hôpital Lapeyronie, Department of Nephrology, Montpellier, France
A longitudinal study comparing hemodialysis with long-term hemodi-
afiltration. Although hemodiafiltration is purported to provide better
cardiovascular stability for dialysis patients; other possible benefits of
this therapy have not been well defined. We have compared treatment
with hemodialysis (HD) and hemodiafiltration (HDF) in 20 stable
patients over a period of 18 months. Dialysis parameters (dialysate
composition and flow, duration, dialyzer) were the same in the two
periods except for the added convection of HDF and a higher tolerated
blood flow in HDF. Cardiovascular parameters were remarkably similar
in the two treatment periods, indicating that stable patients do not
benefit further from this therapy in terms of these factors. The clearance
of urea was significantly improved with HDF, which was reflected in a
higher Kt/V and lower TACur. We observed a significant correlation
between Kt/V and PRU in both HD and HDF modes. This correlation
was linear and the regression line was similar in both modes. The
clearance of beta2-microglobulin was also significantly improved by
HDF compared to HD. Thus the benefit of HDF in stable dialysis
patients is the improved clearance of small molecules and beta2-
microglobulin without increasing dialysis time. Further clinical benefits
due to the improved clearance may only become apparent with longer
follow-up.
The technique of hemodiafiltration (HDF) has existed as an
alternative to hemodialysis (HD) since the early 1970s [1]. This
therapy combines conventional diffusive HD with the convec-
tional component of hemofiltration. Thus while offering good
small molecule clearance it has the potential added benefits of
improved larger molecule clearance and better cardiovascular
stability [2—41. With the development of techniques for on-line
production of sterile infusate from dialysate [51, HDF has
become cheaper and potentially more widely applicable. How-
ever, the true benefits of this form of dialytic therapy have not
been adequately studied. It is not known whether this more
complicated therapy does offer any benefits over conventional
or high flux HD. Do the patients have better clearances of small
or middle molecules? Is it easier to manage calcium and
phosphate balance in these patients? Is their blood pressure
better controlled and are they truly more stable during dialysis?
We attempted to answer these questions by studying a group
of 20 stable patients over 18 months. For the first six months
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they were hemodialyzed and then changed to HDF for the
following 12 months. This occurred in the process of recruit-
ment of patients for a new HDF unit. The duration of dialysis
and the membranes used were the same in both periods.
Comparisons were then made of biochemistry, hematology,
urea kinetics, and cardiovascular parameters for the two peri-
ods. The results indicate that during HDF the clearance of small
and middle molecules is improved compared to HD. However,
there was no change in other biochemical, hematological or
cardiovascular factors.
Methods
Patients
Twenty patients, mean age 58.5 3.0 years (range 22 to 82),
were selected randomly without reference to possible cardio-
vascular disease. All patients, except three, had been main-
tained on RD for at least six months prior to the study, with a
mean interval of 35.7 11 months of HD. The clinical data of
these patients is included in Table 1.
Hemodialysis
HD was performed using G3 ABG-Semca machines (ABG-
Semca, Paris, France) and Fresenius HF-60 or HF-80 polysul-
fone membranes (Fresenius AG, Bad Homburg, Germany).
Ultrapure, sterile, bicarbonate buffered dialysate was used at
500 mI/mm flow rate. The composition of the dialysate was: Na
140.6 0.3 mmol/liter, K 1.70 0.01 mmol/liter, HCO3 34.3
0.3 mmol/liter and Ca 1.75 mmol/liter. The sterility and purity of
our dialysate delivery system has been previously described
[4—61; the dialysate was cultured fortnightly and always con-
tained less than 10 bacteria per liter and had undetectable
endotoxin on Limulus amoebocyte assay. Blood flow rate was
optimized on an individual patient basis and was generally in
the order of 300 to 400 mI/mm. All patients were dialyzed for
three hours, except one for 2½ hours, three times per week.
Hemodiafiltration
HDF was performed using A-2008-C Fresenius machines
modified for HDF (Fresenius AG, Bad Homburg, Germany)
and the same polysulfone membranes as for HD. Sterile infu-
sate was produced by on-line ultrafiltration of dialysate as
previously described [4] and the rate of reinfusion was 80 to 100
mi/mm. Bicarbonate buffered dialysate of the same composition
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Patient
number Age Etiology
Time on
dialysis
months
1 64 Chronic GN 7
2 63 PKD 156
3 61 Calculi 13
4 72 Calculi 27
5 73 Nephrosclerosis 25
6 82 Analgesic nephropathy 24
7 59 Obstruction 7
8 53 Chronic ON 10
9 56 Chronic GN 41
10 71 PKD 5
11 58 Chronic ON 17
12 70 Calculi 12
13 41 Chronic ON 130
14 70 PKD 151
15 31 Chronic ON 1
16 57 Vasculitis 24
17 59 Obstruction 10
18 42 Chronic ON 2
19 66 Chronic ON 19
20 22 Chronic GN 33
Cardiovascular parameters
Pre- and post-dialysis blood pressures were measured while
patients were supine using a Dinamap 8103 blood pressure
monitor (Cntikon, Creteil, France). Weight was constantly
monitored using Gambro weigh beds (Gambro, Sweden) and
the pre- and post-dialysis weights were recorded. The monthly
means for blood pressure and weight from all the dialysis
sessions that month were calculated and were utilized alongside
the other monthly results described above (for weight: the
post-dialysis "dry weight" and the sessional weight loss were
utilized).
Morbidity
As an assessment of crude morbidity, the total number of
in-patient hospital days spent by the patient group was as-
sessed. For the HD period this included the six months prior to
the change to HDF as most patients had been on HD mode for
at least six months prior to the six month assessment period.
For HDF, the second six month period of HDF was assessed.
Thus the patients had been on HDF for six months prior to the
inclusion of morbidity data. This was to avoid the first six
months when HD-related morbidity may still have been opera-
tive.
Adjustment of parameters
as above was used at 600 mI/mm (which equals 500 to 520
mi/mm after production of infusate). In addition to the sterility
checks outlined above, the 0.45 rm filter from the infusate line
was cultured daily; it also was routinely sterile. Blood flow was
again individualized and dialysis duration was the same as for
the HD period. For both HD and HDF, dialyzers were reused
up to 15 times after re-processing with peracetic acid via a
RenatronTM (Renal Systems, Bois D'Arcy, France).
Biochemistry
Monthly assessments of pre-dialysis serum Na, K, HCO3,
total calcium (Ca), phosphate (Phos), urea, creatinine (Cr), total
proteins; and post-dialysis serum urea and total proteins were
made. In addition assessments were made of the serum albumin
and pre- and post-dialysis serum /3,-microglobulin (/32m) levels
once in the two month assessment period. The results for
post-dialysis /32m are expressed after correction for volume
changes as suggested by Bergstrom and Wehle [71.
Hematology
Monthly assessments were made of hemoglobin (Hb), white
cell count (WCC), and lymphocyte count (Lym).
Urea kinetics
Monthly assessments of urea kinetics, allowing for the in-
creased convectional component in HDF, were performed
according to the methods of Farrell and Gotch [8]. This in-
cluded timed bubble speed for blood flow rate assessment,
assessment of angioaccess recirculation (expressed as a mean
of the recirculation of urea and creatinine), and assessment of
residual renal function. The KtIV, PCR and TACurea were duly
calculated. In addition the percent reduction of urea (PRU) was
also calculated and compared to Kt/V.
During the 18 months of the study, adjustments were made to
the patients' care as would normally be required. This included
such aspects as alteration of desired "dry weight," manipula-
tion of phosphate binders and use of antihypertensive agents.
Cost analysis
The two procedures were performed in the same unit so that
the costs of site rental, electricity and nursing time were
considered the same for both procedures. A detailed analysis of
the costs of dialyzers, tubing, concentrate, water treatment and
use, fixed pharmaceuticals (test strips and heparin) and reuse
associated costs was performed. The costs of monitoring the
dialysate composition and quality were also considered the
same for the two procedures.
Inclusion of results and statistics
The study protocol is outlined in Figure 1. The last two
consecutive months of HD prior to the change to HDF were
included as representative of the HD period. For HDF, the
sixth and seventh months after the change were included. This
was done to allow any settling in that may have occurred after
the change. Mean figures for each two month period were
obtained for each patient. The SAS software package was used
for statistical analysis (Statistical Analysis Systems Institute
Inc., Version 5, Cary, North Carolina, USA). The tests used
were: paired t-test for HD versus HDF differences, Pearson's
correlation between numeric variables and regression analysis
to define the relationship between the correlated variables.
Results for the patient population have been expressed as mean
SD. Results were considered significant if P < 0.05.
Results
All 20 patients completed the study period. Eighteen continue
on HDF currently; one of the other two was transplanted and
Table 1. Clinical details of patients dialyzed consecutively for six
months with hemodiatysis, then hemodiafiltration.
Abbreviations are: Chronic ON, chronic glomerulonephritis; PKD,
polycystic kidney disease.
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Fig. 1. Outline of the project protocol. The
period indicated as 'biochem" represents the0 2 4 6/0 2 4 6 8 10 12 period of assessment of biochemistry,
I I hematology, urea kinetics and cardiovascular
parameters. The periods of "morbidity"
Morbidity Morbidity represents periods of 6 months for assessment
of morbidity after already having experiencedBiochem Biochem that dialysis mode for 6 months.
Table 2. Biochemical and derived kinetic data following change of
dialysis mode from hemodialysis to hemodiafiltration in 20 dialysis
patients
Measured quantity units HD HDF P value
Statistically significant factors
Urea-before mmol/liter 28.8 6.2 25.3 5.7 0.0024
Urea-after mmol/liter 9.2 2.7 7.4 3.0 0.0001
/32m-after mg/liter (corrected) 14.6 4.9 11.4 3.9 0.0146
Blood flow mI/mm 348 33 369 24 0.0022
Kt/V 1.41 0.23 1.55 0.32 0.0005
TACurea mmol/liter 19.3 4.3 16.3 4.5 0.0001
Statistically insignificant factors
Na mmol/liter 137.4 0.5 137.7 0.5
K mmol/liter 5.1 0.1 5.1 0.1
HCO3 mmol/liter 21.5 0.4 21.9 0.3
Ca mmol/liter 2.48 0.03 2.49 0.03
Phos mmol/liter 1.75 0.10 1.73 0.09
132m-before mg/liter 32.6 1.6 30.5 2.5
Recirculation% 15.3 1.3 15.6 1.4
Residual renal function ml/min 0.91 0.31 0.51 0.16
Dialysis parameters were unaltered apart from the addition of the
convective component of hemodiafiltration. Note also the improved
blood flow tolerated with HDF. Results are from two month periods
after six months of the relevant mode of therapy.
the other now undergoes HD at home. HDF was well tolerated
by all the patients. The biochemical and kinetic data during the
periods of HD and HDF are presented in Table 2. Of particular
note are the improved clearance for small molecules as evi-
denced by the improved pre- and post-dialysis serum urea
levels and perhaps more importantly the improved TACurea and
Kt/V levels. Note however that the serum creatinine levels
were not significantly different (being 953 32 mol/liter for
HD, and 929 32 mol/liter for HDF). Despite the lower
TACurea levels with HDF, the results for PCR were not altered
significantly (being 1.21 0.31 g/kg/day for HD, and 1.11
0.43 g/kg/day for HDF) indicating that the lowered TACurea was
not achieved at the expense of the patients' nutrition. It is also
important to note that the improved urea kinetics were in part
due to the increased blood flow tolerated during HDF.
The corrected serum p2m level post-dialysis was significantly
decreased during HDF compared to HD; this was despite
similar pre-dialysis serum levels (HD 32.0 7.6 mg/liter; HDF
30.6 7.6 mg/liter, P = NS). Thus the percent reduction in f32m
in the course of dialysis was greater with HDF treatment than
with HD (Fig. 2). There was a greater increase in percent
reduction of /32m than in percent reduction of urea with the
change to HDF (54.8 to 62.7% for f32m; 68.7 to 71.6% for urea).
In addition to those factors detailed in Table 2, there was no
Fig. 2. The percent reductions in urea and beta2-microglobulin during
hemodialysis and hemodiafiltration in 20 patients. Dialysis parameters
were the same for both modes apart from the additive convection of
hemodiafiltration and improved blood flow in HDF mode. *JJ < 0.05;
**p < 0.005 by Student's 1-test for paired data.
Table 3. Effects of changing dialysis mode from hemodialysis to
hemodiafiltration on blood pressure and weight parameters in 20
stable patients
Parameter HD HDF
Pre-dialysis BP 147/76 148/78
Post-dialysis BP 132/75 135/74
Dry weight kg 61.9 11.7 61.0 12.3
Weight loss per session kg 2.46 0.86 2.50 0.81
Wt loss as % dry weight 3.97% 4.10%
significant change in the following parameters: Aib, total pro-
teins (pre- or post-dialysis), recirculation, Hb, WCC, Lym,
systolic or diastolic BP either pre- or post-dialysis), dry weight,
or weight loss achieved during dialysis. Dialysis related symp-
toms and episodic hypotension were rare in both modes and not
significantly different. The amount of phosphate binders re-
quired was not altered in the two halves of the study, nor were
the antihypertensive medications. The cardiovascular and
weight related parameters were strikingly similar during HD
and HDF (Table 3).
Change to
HDF
Fig. 3. The relationship of the "percent
reduction in urea" to the formally calculated
Kt/V result in 20 patients in hemodialysis
(triangles) and hemodiafiliration (diamonds)
modes. Regression analysis revealed the
9r following formulae: for hemodialysis Kt/V =V 0.O39PRU-1.33, r = 0.912, P < 0.0001; for
hemodiafiltration Kt/V = 0.O37PRU-l.14, r =
0.865, P < 0.0001.
There was a strong correlation between PRU and KtIV: r =
0.889, P <0.0001. Regression analysis provided similar formu-
lae for the relationship of PRU and Kt/V in both HD and HDF
modes: for HD, KtIV = 0.0393PRU-1 .33, r = 0.912,P <0.0001;
and for HDF, Kt/V = 0.0372PRU-l.14, r 0.865, P < 0.0001
(Fig. 3).
Hospital days were different between the two modes. For the
HD period there were a total of 76 hospital bed days occupied
by the patients, whereas for the HDF period there were 26 days
occupied. In both of these periods there were several in-patient
stays for AV access related problems. If these are subtracted
the in-patients days were 41 days for HD and 17 days for HDF.
There was no single episode of protracted length in either study
period.
The cost analysis demonstrated that HDF, perhaps surpris-
ingly, was no more expensive than HD (97% of HD costs). The
on-line production of infusate is the predominant cost saver and
the actual cost of this was offset by an increased use of
reprocessed dialyzers in the HDF period. This analysis has,
though, ignored the different initial costs of the HDF machines
as opposed to the HD machines.
Discussion
The technique of HDF has frequently been considered to be
a better mode of dialysis for patients with cardiovascular
instability [2—4]. The results presented here do not bear this out;
there being no difference in the pre- or post-dialysis blood
pressure in HDF mode compared to HD. This is particularly
relevant as there was also no difference in the weight loss
achieved during the session, Hence for a given weight loss, the
patients still experienced the same drop in blood pressure in the
course of dialysis with HDF as with HD. There are two possible
reasons why a difference was not detected. Firstly, we did not
assess the intradialytic blood pressures but only those at the
start and finish of dialysis. Such additional assessment may
reveal some fluctuations in blood pressure. Secondly, the
patients were not selected for cardiovascular instability; on the
whole they were a relatively stable group with only rare
hypotensive episodes even in HD mode. This latter point may
in part relate to the quality of the ultrapure, sterile water with
the subsequent avoidance of possible bacterial or endotoxin
contamination of the dialysate [6]. Endotoxin contamination
has been considered by some to be a prominent cause of
dialysis related signs and symptoms [9]. In addition, the com-
mon use of reprocessed dialyzers avoided frequent potential
type 2 "first use symptoms" [10]. We have separately examined
a group of patients with cardiovascular pathology and found
improved tolerance of dialysis in this group when treated with
HDF [11].
Overall, the differences between the two dialysis modes was
not marked: biochemical and hematological parameters in par-
ticular were not significantly different apart from the expected
better clearances with HDF [12, 13]. This is despite a previous
report suggesting improvement in anemia with the use of
long-term HDF [14]. The addition of the convective component
of HDF appeared to add 10 to 15% to the observed Kt/V which
has been previously demonstrated [2, 4]. In a similar fashion,
the TACurea results were lower in the HDF sessions by approx-
imately 15%. The blood flow rate also increased by 6.2% and
the PCR decreased a little; however, these changes are unlikely
to account for the increased Kt/V themselves, especially at the
blood flow rates utilized. However, it is unknown whether a
KtIV result of 1.55 is significantly better for the patient than a
result of 1.41, despite the statistical significance of the result.
The original NCDS study suggested a result of 1.0 as adequate
for Kt/V [151, but recent evidence would suggest that there is a
direct correlation of higher Kt/V values with better patient
survival [16]. It has also been demonstrated that the protein
catabolic rate (PCR) directly correlates with Kt/V and that this
is dependent on the membrane used, as higher flux membranes
require a lower Kt/V to achieve a similar PCR [17]. As an
extension of this, it has been suggested that it is the PCR (and
thus the nutritional status of the patient) which is a better
reflector of the patient survival [17]. Thus we should be aiming
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for better nutrition and indirectly, higher Kt/V values for our
patients.
The percent reduction of /32microglobulin with HDF was also
better than in the HD mode, as has been previously reported
[18—20]. This in itself may carry considerable significance as
dialysis related amyloidosis has become a major problem in our
aging dialysis population [21]. If a particular dialysis mode were
associated with a genuine lower incidence of dialysis related
amyloidosis then it would be welcomed. However, at present,
the mere occurence of lower post-dialysis /32m levels (and
certainly not normal levels) is not sufficient evidence to suggest
this. This is particularly so when it is apparent that the
pre-dialysis levels did not decrease at all after six months of
HDF. It has recently been reported that the generation rate of
f32m is the same in those with renal failure and those with
normal renal function [22]. A previous report in children also
failed to demonstrate a fall in pre-dialysis 2m levels over a five
year period of HDF [23]. Pre-dialysis 132m levels have been
reported to fall with ongoing HDF in two studies but follow-up
periods have been short (2 and 2'/2months) [18, 241. It has been
further reported that HDF using large volumes of infusate (60
liters) is also associated with a gradual decrease in pre-dialysis
f32m levels [25, 261. Despite this, it has recently been demon-
strated, using a three compartment model, that intermittent
dialysis can at best remove half the weekly load of f32m [22]. It
is therefore obvious that even the augmented clearance of 132m
by HDF using highly permeable polysulfone membranes is in no
way adequate to clear the normal daily load of 132m and thus
prevent dialysis related amyloidosis. It is apparent though that
the convective component of HDF adds more to the clearance
of f32m than it does to small molecule clearance; this provides a
lower time averaged concentration of /32m than in HD thus
reducing the risk exposure time for f32m related pathology. It is
still unknown, however, whether HDF can clinically reduce the
incidence of dialysis related amyloidosis.
The calcium and phosphate balance remained stable in the
HDF period compared to the HD period, with no change in the
serum levels of either parameter. The use of phosphate binders
was unrestricted in the course of the study but did not differ
from one mode to the other (data not shown). In general the
patients were maintained on CaCO3 as the prime phosphate
binder, however, there was also some A1(OH)3 used. Perhaps
the lack of better control of Phos is not surprising for HDF as
the elimination of Phos is restricted by the movement of Phos
from the intracellular compartment [12], rather than by the
limits of dialysis efficacy.
As well as the improvement in small molecule clearance
reflected in the KtIV and TACurea, it was also evident that there
was an excellent correlation between the calculated urea kinetic
parameters and the serum urea and creatinine levels; for
example creatinine versus Kt/V, r = —0.547, P < 0.0005.
However, perhaps even more striking was the correlation
between PRU and Kt/V. The percent reduction in urea is simple
to calculate and can be done so at considerable cost saving
compared to formal calculation of Kt/V. The derived regression
formulae are very similar to that previously published by Jindal,
Manuel and Goldstein for use in HD [27]. These results confirm
those of previous studies demonstrating the benefit of using
PRU to estimate Kt/V [27, 28]. They also demonstrate that this
technique is equally applicable to HDF.
The morbidity data provided is crude and cannot be over-
stated. It does suggest that HDF was associated with fewer
in-patient hospital days. However, the overall number of hos-
pital days is low and the bulk of the stays were for AV access
related problems. In the HD period there were also 16 hospital
days related to problems from past renal grafts that had been
left in situ. Thus the difference between the two techniques,
allowing for these factors, becomes minimal. However, a longer
period of follow-up with parallel cohorts may have provided
further answers in this regard.
The cost analysis demonstrates that HDF can no longer be
considered an expensive treatment option. A prerequisite for
this, however, is the in-house production of sterile, ultrapure
infusate (and dialysate) and the reprocessing of dialyzers.
In conclusion, long-term HDF provided two advantages over
HD. Firstly it provided 10 to 15% better clearances of small
molecules, such as urea, with the use of similar dialyzers and
dialysis time. If one is striving for higher clearances then this is
a definite advantage. In addition, the clearances of /32m were
also improved, however, the significance of this cannot be
determined currently. Whether HDF offers better cardiovascu-
lar stability for a selected group of patients was not evident
from this study. When applied to a group of patients who are
otherwise stable, there is no appreciable difference in cardio-
vascular events between HD and HDF. There were no apparent
advantages in either blood pressure control or management of
the calciumlphosphate balance.
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